Sol-Gel Technologies Profit Margin 2016-2023 | SLGL

Current and historical gross margin, operating margin and net profit margin for Sol-Gel Technologies (SLGL) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Sol-Gel Technologies net profit margin as of December 31, 2023 is -1331.01%.
Sol-Gel Technologies Annual Profit Margins
Sol-Gel Technologies Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.024B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.776B 5.34
Dr Reddy's Laboratories (RDY) India $11.900B 18.82
Aspen Pharmacare (APNHY) South Africa $5.172B 0.00
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.164B 2.47
Amphastar Pharmaceuticals (AMPH) United States $1.957B 13.40
Supernus Pharmaceuticals (SUPN) United States $1.587B 0.00
Taysha Gene Therapies (TSHA) United States $0.458B 0.00
Generation Bio (GBIO) United States $0.198B 0.00
Assembly Biosciences (ASMB) United States $0.071B 0.00
Personalis (PSNL) United States $0.061B 0.00
Acasti Pharma (ACST) Canada $0.030B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00